Role of probiotics in seizure control
Not Applicable
- Conditions
- Health Condition 1: G409- Epilepsy, unspecified
- Registration Number
- CTRI/2023/03/050814
- Lead Sponsor
- one
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Children 1 -18 years age group
2.Those diagnosed with Epilepsy as per ILAE 2017 criteria with 3 or more self-reported seizure in last 6 months.
3.Acceptance and informed consent for inclusion of patient in study protocol.
Exclusion Criteria
1. <1 year of age
2.Chronic gastrointestinal disease.
3.Hepatic and Renal insufficiency.
4.Immunocompromised.
5.Use of antibiotics, probiotics or anti-inflammatory drugs in past 3 months.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction in seizure frequency at 6 months follow up as compared from baseline seizure frequencyTimepoint: Baseline, 3 months and 6 months
- Secondary Outcome Measures
Name Time Method Incidence of treatment emergent adverse events (safety and tolerability) like allergic reactions, gastrointestinal upset in the form of diarrhea, bloating, flatulence.Timepoint: 3 months and 6 months and as reported